C&G Editor in Chief, Erin Harris

  1. Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook 5/13/2026

    At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.

  2. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

  3. Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D 4/27/2026

    Sana Biotechnology and Mayo Clinic are partnering to standardize delivery of a one-time hypoimmune cell therapy, aiming to scale access and redefine care for type 1 diabetes.

  4. Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry 4/17/2026

    Here's why trafficking and entry remain key barriers to CAR T success in solid tumors.

  5. Target Selection Drives The Future Of CAR T Therapy In Solid Tumors 4/13/2026

    Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.

  6. Mitigating Challenges In Solid Tumor Delivery 4/3/2026

    CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.

  7. Ensuring Quality Of CGT Materials 3/24/2026

    Here's why strong material selection, risk-based controls, and early analytics are critical for successful CGT development.

  8. Building Harmonized Real‑World Data In Oncology 3/13/2026

    Experts at PMWC 2026 emphasized that regulatory‑grade real‑world data in oncology will require prospectively collected, harmonized datasets that integrate multimodal clinical information.

  9. The In Vivo Cell Therapy Shift On Display At PMWC 2026 3/10/2026

    At PMWC 2026 in Santa Clara, we saw how in vivo CAR T and MRD‑guided strategies could reshape cell therapy by moving curative intent earlier while balancing bold innovation with practical scalability.

  10. Inside SynaptixBio's Mission To Develop A Therapy For H-ABC 3/9/2026

    SynaptixBio's Dr. Dan Williams discusses the company’s effort to develop an antisense oligonucleotide therapy that silences the mutant TUBB4A gene in the ultra-rare leukodystrophy H-ABC, highlighting the scientific, regulatory, and funding challenges of advancing treatments for extremely small patient populations.